Aclaris Therapeutics (ACRS) Short Interest Ratio & Short Volume $2.02 -0.04 (-1.70%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aclaris Therapeutics Short Interest DataAclaris Therapeutics (ACRS) has a short interest of 5.98 million shares. This marks a -8.70% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.2, indicating that it would take 5.2 days of the average trading volume of 955,112 shares to cover all short positions.Current Short Interest5,980,000 sharesPrevious Short Interest6,550,000 sharesChange Vs. Previous Month-8.70%Dollar Volume Sold Short$11.18 millionShort Interest Ratio5.2 Days to CoverLast Record DateAugust 15, 2025Outstanding Shares108,330,000 sharesPercentage of Shares Shorted5.52%Today's Trading Volume535,497 sharesAverage Trading Volume955,112 sharesToday's Volume Vs. Average56% Short Selling Aclaris Therapeutics? Sign up to receive the latest short interest report for Aclaris Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartACRS Short Interest Over TimeACRS Days to Cover Over TimeACRS Percentage of Float Shorted Over Time Aclaris Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/15/20255,980,000 shares $11.18 million -8.7%N/A5.2 $1.87 7/31/20256,550,000 shares $10.02 million -15.8%6.4%6 $1.53 7/15/20257,780,000 shares $11.83 million +3.9%N/A8.5 $1.52 6/30/20257,490,000 shares $10.64 million +54.8%7.4%7.9 $1.42 6/15/20254,840,000 shares $7.11 million +3.0%4.8%6.2 $1.47 5/31/20254,700,000 shares $6.82 million +2.8%7.0%5.2 $1.45 5/15/20254,570,000 shares $5.58 million +2.7%6.8%5.3 $1.22 4/30/20254,450,000 shares $6.14 million +9.3%N/A5.1 $1.38 4/15/20254,070,000 shares $4.56 million -34.8%6.1%4.5 $1.12 3/31/20256,240,000 shares $9.55 million +3.5%9.3%6.9 $1.53 Get the Latest News and Ratings for ACRS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/15/20256,030,000 shares $9.41 million +26.7%9.0%6.5 $1.56 2/28/20254,760,000 shares $9.47 million -5.2%7.1%5.8 $1.99 2/15/20255,020,000 shares $11.70 million +28.1%7.5%5 $2.33 1/31/20253,920,000 shares $9.72 million +15.6%N/A1.6 $2.48 1/15/20253,390,000 shares $8.51 million -4.8%N/A1.3 $2.51 12/31/20243,560,000 shares $8.83 million +12.7%N/A1.5 $2.48 12/15/20243,160,000 shares $10.18 million +27.4%N/A1.4 $3.22 11/30/20242,480,000 shares $10.09 million +59.0%N/A1.1 $4.07 11/15/20241,560,000 shares $3.20 million -35.3%N/A0.7 $2.05 10/31/20242,410,000 shares $4.36 million +73.4%N/A4.6 $1.81 10/15/20241,390,000 shares $1.64 million -19.7%N/A4.1 $1.18 9/30/20241,730,000 shares $1.99 million +1.2%N/A3.6 $1.15 9/15/20241,710,000 shares $2.02 million -0.6%N/A2.4 $1.18 8/31/20241,720,000 shares $2.03 million -4.4%N/A2.2 $1.18 8/15/20241,800,000 shares $2.12 million -3.2%N/A2.2 $1.18 7/31/20241,860,000 shares $2.49 million -13.9%N/A2.1 $1.34 7/15/20242,160,000 shares $2.92 million -45.2%N/A2.4 $1.35 6/30/20243,940,000 shares $4.33 million -11.7%N/A4.7 $1.10 6/15/20244,460,000 shares $5.26 million -3.3%N/A6.5 $1.18 5/31/20244,610,000 shares $4.75 million -5.3%N/A6.3 $1.03 5/15/20244,870,000 shares $5.75 million -18.2%N/A5.4 $1.18 4/30/20245,950,000 shares $7.20 million +19.2%N/A5.6 $1.21 4/15/20244,990,000 shares $6.04 million +2.0%N/A4.5 $1.21 3/31/20244,890,000 shares $6.06 million -4.5%N/A3 $1.24 3/15/20245,120,000 shares $5.99 million -16.1%N/A2.9 $1.17 2/29/20246,100,000 shares $7.26 million +4.6%N/A2.8 $1.19 2/15/20245,830,000 shares $7.17 million -7.9%N/A2.4 $1.23 1/31/20246,330,000 shares $7.34 million -0.5%N/A1.3 $1.16 1/15/20246,360,000 shares $5.88 million +9.8%N/A1.3 $0.92 12/31/20235,790,000 shares $6.08 million -2.0%N/A1.3 $1.05 12/15/20235,910,000 shares $5.97 million +24.2%N/A1.4 $1.01 11/30/20234,760,000 shares $4.16 million -35.6%N/A1.1 $0.87 11/15/20237,390,000 shares $5.92 million +12.3%N/A2 $0.80 10/31/20236,580,000 shares $32.77 million +8.8%N/A6.5 $4.98 10/15/20236,050,000 shares $32.19 million +2.0%N/A7.2 $5.32 9/30/20235,930,000 shares $40.62 million -9.1%N/A7.8 $6.85 9/15/20236,520,000 shares $49.23 million +14.4%N/A9.1 $7.55 8/31/20235,700,000 shares $42.64 million +10.5%N/A8.3 $7.48 8/15/20235,160,000 shares $40.09 million -1.0%N/A8.4 $7.77 7/31/20235,210,000 shares $51.42 million +4.2%N/A8.7 $9.87 7/15/20235,000,000 shares $54.75 million -5.3%N/A7.9 $10.95 6/30/20235,280,000 shares $54.75 million +14.0%N/A8.2 $10.37 6/15/20234,630,000 shares $45.88 million -2.7%N/A6.5 $9.91 5/31/20234,760,000 shares $39.75 million +2.4%N/A6.8 $8.35 5/15/20234,650,000 shares $38.69 million -5.3%N/A4.5 $8.32 4/30/20234,910,000 shares $43.65 million -1.4%9.8%4.4 $8.89 4/15/20234,980,000 shares $44.02 million +3.8%9.9%4.4 $8.84 3/31/20234,800,000 shares $38.83 million +14.8%9.5%4.4 $8.09 3/15/20234,180,000 shares $33.40 million +26.7%8.1%4.2 $7.99 2/28/20233,300,000 shares $41.12 million +8.9%6.4%3.7 $12.46 2/15/20233,030,000 shares $39.66 million +14.3%5.9%5.4 $13.09 1/31/20232,650,000 shares $44.79 million -6.7%5.2%5.8 $16.90 1/15/20232,840,000 shares $50.98 million -5.0%5.5%8.1 $17.95 12/30/20222,990,000 shares $47.09 million +12.4%5.8%9 $15.75 12/15/20222,660,000 shares $41.63 million -4.0%5.2%7.9 $15.65 11/30/20222,770,000 shares $42.16 million -14.0%5.4%7.8 $15.22 11/15/20223,220,000 shares $57.90 million -12.5%6.3%9.4 $17.98 10/31/20223,680,000 shares $57.44 million -4.9%7.1%10.9 $15.61 10/15/20223,870,000 shares $60.84 million +7.2%7.5%11.4 $15.72 9/30/20223,610,000 shares $56.82 million +9.4%7.0%11.3 $15.74 9/15/20223,300,000 shares $47.49 million +5.1%6.4%9.5 $14.39 8/31/20223,140,000 shares $49.96 million -10.0%6.1%8.9 $15.91 8/15/20223,490,000 shares $58.49 million -1.4%6.8%9.8 $16.76 7/31/20223,540,000 shares $54.55 million -9.0%N/A9.3 $15.41 7/15/20223,890,000 shares $59.28 million +3.2%N/A10.2 $15.24 6/30/20223,770,000 shares $52.63 million +5.6%N/A7.9 $13.96 6/15/20223,570,000 shares $52.66 million +1.4%N/A7.2 $14.75 5/31/20223,520,000 shares $45.02 million +37.5%6.9%7.5 $12.79 5/15/20222,560,000 shares $27.26 million +20.2%5.0%5.3 $10.65 4/30/20222,130,000 shares $26.24 million -8.6%4.5%4.3 $12.32 4/15/20222,330,000 shares $39.63 million -16.2%5.0%4.6 $17.01 3/31/20222,780,000 shares $47.93 million +2.2%6.0%5.9 $17.24 3/15/20222,720,000 shares $41.34 million +3.4%5.8%6 $15.20 2/28/20222,630,000 shares $39.19 million +14.4%5.6%5.7 $14.90 2/15/20222,300,000 shares $29.30 million +10.6%4.9%4.9 $12.74 1/31/20222,080,000 shares $22.71 million +7.8%4.8%4.7 $10.92 1/15/20221,930,000 shares $20.86 million -5.9%4.1%4.6 $10.81 12/31/20212,050,000 shares $29.81 million +0.5%4.3%5.3 $14.54 12/15/20212,040,000 shares $27.97 million +8.5%4.3%4.9 $13.71 11/30/20211,880,000 shares $24.06 million -0.5%4.0%4.3 $12.80 11/15/20211,890,000 shares $27.48 million -15.3%4.0%4.3 $14.54 10/29/20212,230,000 shares $38.69 million -19.2%4.9%5.3 $17.35 10/15/20212,760,000 shares $46.40 million -14.3%6.1%6.7 $16.81 9/30/20213,220,000 shares $57.96 million +9.2%7.1%7.3 $18.00 9/15/20212,950,000 shares $52.24 million +8.1%6.5%5.4 $17.71 8/31/20212,730,000 shares $44.25 million -12.8%6.0%4.4 $16.21 8/13/20213,130,000 shares $46.07 million +0.6%7.0%4.5 $14.72 7/30/20213,110,000 shares $46.43 million -11.4%6.4%4.3 $14.93 7/15/20213,510,000 shares $53.07 million -13.1%7.4%4.6 $15.12 6/30/20214,040,000 shares $70.94 million +61.0%9.3%5.2 $17.56 6/15/20212,510,000 shares $44.70 million +32.8%5.8%3.5 $17.81 5/28/20211,890,000 shares $42.03 million No Change4.9%2.7 $22.24 5/14/20211,890,000 shares $40.14 million +9.9%4.9%3.2 $21.24 4/30/20211,720,000 shares $42.90 million +16.2%4.7%2.6 $24.94 4/15/20211,480,000 shares $41.17 million +62.4%4.1%1.8 $27.82 3/31/2021911,100 shares $21.48 million +41.5%2.5%0.3 $23.58 3/15/2021644,000 shares $16.24 million -15.2%1.8%0.2 $25.21 2/26/2021759,000 shares $16.11 million -47.7%1.9%0.3 $21.22 2/12/20211,450,000 shares $33.74 million +52.7%3.9%0.5 $23.27 1/29/2021949,600 shares $18.54 million +69.1%2.7%0.3 $19.52 1/15/2021561,500 shares $3.43 million -18.4%1.6%0.2 $6.10 12/31/2020688,200 shares $4.56 million +42.2%2.2%1.1 $6.62 12/15/2020484,000 shares $1.90 million -12.8%1.6%0.7 $3.93 11/30/2020555,300 shares $1.84 million -9.4%1.8%1.4 $3.32 11/15/2020613,200 shares $2.23 million -10.1%2.0%1.5 $3.64 10/30/2020682,300 shares $2.61 million +5.7%2.2%1.6 $3.83 10/15/2020645,400 shares $2.58 million -6.7%2.0%1.3 $4.00 9/30/2020691,500 shares $1.78 million +17.0%2.1%1.1 $2.57 9/15/2020591,100 shares $1.39 million -12.0%1.8%0.9 $2.35 ACRS Short Interest - Frequently Asked Questions What is Aclaris Therapeutics' current short interest? Short interest is the volume of Aclaris Therapeutics shares that have been sold short but have not yet been closed out or covered. As of August 15th, investors have sold 5,980,000 shares of ACRS short. Learn More on Aclaris Therapeutics' current short interest. What is a good short interest ratio for Aclaris Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ACRS shares currently have a short interest ratio of 5.0. Learn More on Aclaris Therapeutics's short interest ratio. Is Aclaris Therapeutics' short interest increasing or decreasing? Aclaris Therapeutics saw a decline in short interest in August. As of August 15th, there was short interest totaling 5,980,000 shares, a decline of 8.7% from the previous total of 6,550,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Aclaris Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Aclaris Therapeutics: Akebia Therapeutics, Inc. (9.36%), Anavex Life Sciences Corp. (29.54%), Immunome, Inc. (17.35%), Iovance Biotherapeutics, Inc. (24.38%), Taysha Gene Therapies, Inc. (13.35%), ArriVent BioPharma, Inc. (26.49%), Day One Biopharmaceuticals, Inc. (15.68%), Dianthus Therapeutics, Inc. (25.54%), Valneva SE Sponsored ADR (0.09%), Ginkgo Bioworks Holdings, Inc. (17.53%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Lucid Group, Inc. ($8.00 billion), Spotify Technology ($5.48 billion), AppLovin Corporation ($5.11 billion), Reddit Inc. ($5.02 billion), Coinbase Global, Inc. ($3.99 billion), Charter Communications, Inc. ($3.89 billion), Live Nation Entertainment, Inc. ($3.18 billion), Seagate Technology Holdings PLC ($2.59 billion), ResMed Inc. ($2.55 billion), and Rocket Lab Corporation ($2.52 billion). View all of the most shorted stocks. What does it mean to sell short Aclaris Therapeutics stock? Short selling ACRS is an investing strategy that aims to generate trading profit from Aclaris Therapeutics as its price is falling. ACRS shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Aclaris Therapeutics? A short squeeze for Aclaris Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ACRS, which in turn drives the price of the stock up even further. How often is Aclaris Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ACRS, twice per month. The most recent reporting period available is August, 15 2025. More Short Interest Resources from MarketBeat Related Companies AKBA Short Interest AVXL Short Interest IMNM Short Interest IOVA Short Interest TSHA Short Interest AVBP Short Interest DAWN Short Interest DNTH Short Interest VALN Short Interest DNA Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ACRS) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRS Stock Alerts